Form D · Pharmaceuticals

EAGLE PHARMACEUTICALS, INC.

Woodcliff Lake, NJ · CIK 0000827871

Offering snapshot reported Nov 23, 2016 · SEC filing

Reported sold: $2.74M
Investors reported: 2
Minimum accepted: $0
First sale: Nov 16, 2016

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Nov 23, 2016	Initial	$2,740,728	No comparison	2	SEC filing
Feb 18, 2011	Initial	$12,348,194	No comparison	18	SEC filing
Aug 11, 2008	Paper	Not reported	No comparison	Not reported	SEC filing
Feb 28, 2007	Paper	Not reported	No comparison	Not reported	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: Yes
Business combination: Yes

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-275107

Total offering amount includes $48,000,000 of milestone payments. Such payments shall be made only if certain milestones are met. The seller may elect to receive milestone payments in stock or cash.

Source: Form D, filed Nov 23, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Douglas L. Braunstein	Director
John C. Deighan	Executive
Sander Flaum	Director
Robert L. Glenning	Director
Michael Graves	Director
Adrian Hepner	Executive
Steven L. Krill	Executive
David Pernock	Director
Steven Ratoff	Director
David E. Riggs	Executive
Gregg Stetsko	Executive
Scott Tarriff	Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

50 Tice Boulevard, Suite 315
Woodcliff Lake, NJ, 07677